MSB

0.51%

97.0¢

MESOBLAST LIMITED

Market Cap $1.107B Add to my watchlist

Healthcare Biotechnology

Mesoblast Limited is an Australia-based company, which is engaged in developing... Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.More

RCE'S BREAKTHROUGH

Synthetic anti-infective developer Recce Pharmaceuticals Ltd (ASX:RCE) has made inroads for recognition of its RECCE® 327 Gel (or R327G) as a topical treatment for burn wound infections, gaining a US$2 million grant from the US Department of Defense...

Latest Threads

Tag

Subject

MSB

Ann: Class Action Resolution

2 3

18:24

145

34K

18:24

Last post gavint66

145

34K

MSB

Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L

4 5 6

14:15

314

133K

14:15

Last post nippy

314

133K

MSB

banter and General Discussion

176 177 178

11:45

10K

3.2M

11:45

Last post nippy

10K

3.2M

MSB

MESO Nasdaq update

94 95 96

11:14

5.7K

2.8M

11:14

Last post Aremac

5.7K

2.8M

MSB

Pick Today's Price Range Low-High... Just for Fun

20 21 22

21/08/24

1.3K

404K

21/08/24

Last post Mikesmith1981

1.3K

404K

MSB

Cell Therapy News/Articles

299 300 301

21/08/24

18K

6.9M

21/08/24

Last post Wilba32

18K

6.9M

MSB

chart

2 3

21/08/24

154

76K

21/08/24

Last post Wilba32

154

76K

MSB

Chart

20/08/24

7.8K

20/08/24

Last post Ichimokou

7.8K

See All Discussions

Timeline

Class Action Resolution
21 Aug 19:07	Share

Quarterly Activities/Appendix 4C Cash Flow Report
31 Jul 09:53	Share

FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L
23 Jul 14:18	Share

Confirmatory Phase 3 Back Pain Trial Actively Enrols
22 Jul 09:07	Share

Appendix 3Y for Philip Krause
12 Jul 17:27	Share

Notification regarding unquoted securities - MSB
12 Jul 17:18	Share

Notification of cessation of securities - MSB
12 Jul 17:09	Share

Change in substantial holding
12 Jul 08:22	Share

Mesoblast Resubmits BLA with FDA for Ryoncil Approval
09 Jul 09:55	Share

Mesoblast to File BLA for Ryoncil FDA Approval Next Week
01 Jul 15:00	Share

Mesoblast Corporate Presentation at Investor Conference
03 Jun 09:27	Share

Corporate Presentation
03 Jun 09:22	Share

Appendix 3Y for Eric Rose
10 May 09:22	Share

Appendix 3Y for Eric Rose
03 May 09:49	Share

Change in substantial holding
02 May 09:49	Share

Quarterly Activities/Appendix 4C Cash Flow Report
30 Apr 09:59	Share

Mesoblast Chair Transition
30 Apr 09:47	Share

Appendix 3Y for Jane Bell
16 Apr 09:18	Share

Application for quotation of securities - MSB
16 Apr 09:15	Share

Notification regarding unquoted securities - MSB
16 Apr 09:06	Share

Notification of cessation of securities - MSB
15 Apr 17:02	Share

Change in substantial holding
09 Apr 09:23	Share

Change in substantial holding
02 Apr 09:53	Share

FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
26 Mar 13:05	Share

Pause in Trading
26 Mar 09:52	Share

Cleansing Notice
26 Mar 09:48	Share

Application for quotation of securities - MSB
22 Mar 16:32	Share

Change in substantial holding
20 Mar 09:46	Share

Proposed issue of securities - MSB
20 Mar 09:37	Share

Cleansing Notice
19 Mar 08:45	Share

View More

(20min delay)
Last 97.0¢		Change -0.005(0.51%)		Mkt cap ! $1.107B

Open	High	Low	Value	Volume
98.5¢	98.5¢	96.0¢	$2.168M	2.226M

Buyers (Bids)

No.	Vol.	Price($)
1	16000	96.5¢

Sellers (Offers)

Price($)	Vol.	No.
97.0¢	86854	7

View Market Depth

No.	Vol.	Price($)
1	16000	0.965
1	23000	0.960
4	56273	0.955
5	46225	0.950
2	65500	0.945

Price($)	Vol.	No.
0.970	50000	2
0.975	20000	1
0.980	894	1
0.985	48122	2
0.990	54328	5

Last trade - 16.10pm 23/08/2024 (20 minute delay)


Last 96.0¢		Change -0.005 ( 2.10 %)
Open	High	Low	Volume
97.5¢	98.5¢	96.0¢	400082
Last updated 15.59pm 23/08/2024 ?

MSB (ASX) Chart

MESOBLAST LIMITED

Latest Threads

Timeline

Featured News

Latest Videos

Mesoblast (ASX:MSB) flags strengthened heart function in latest trial results

28 Feb 2023 10:07 (AEDT)

Latest Articles

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Mesoblast shares fell -4.45% in the first hour of trades on Tuesday as the company announced it has to resubmit an application to the FDA.

Mesoblast (ASX:MSB) completes $97M funding round heading into Q2

Mesoblast (ASX:MSB) has completed its pro-rata accelerated non-renounceable entitlement offer, launched on December 4, 2023.

Mesoblast (ASX:MSB) gains FDA approval to fast-track Revascor in end-stage heart failure

Mesoblast (ASX:MSB) has received U.S. FDA approval to accelerate rexlemestrocel-L (Revascor) for patients with end-stage ischemic heart failure and reduced ejection fraction (HFrEF) with a left ventricular assist device (LVAD).

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News